Intuitive Surgical (ISRG) continues its bullish streak, as its shares hit a 52-week high due in part to Hennion & Walsh Asset Management Inc. and Hodges Capital Management increasing their stakes. Intriguing options now available indicate strong investor interest. Despite underperforming compared to competitors, ISRG outpaces stock market gains. However, some unease remains about its returns on capital. FDA clearance for a new product offering, the unveiling of a new robotic system, and impressive Q1 2024 earning results all contribute to the positive outlook. Even with the stock’s fluctuations amid broader market trends, analysts indicate it is the ‘Best of Breed’ stock for Q3. Yet external threats abound, especially with the rise in autonomous operations in robotic surgery. Despite these challenges, investing in ISRG is recommended by Wall Street, with one analyst even suggesting a 20% upside. The robust Q4 earnings growth and procedure expansion have given further impetus for retaining ISRG in portfolios, including those of Ray Dalio and SOTD. Essentially, the company’s stronghold in the field of robotic surgery, coupled with its operational leverage, make ISRG a compelling choice for investors.
Intuitive Surgical ISRG News Analytics from Tue, 09 Jan 2024 08:00:00 GMT to Sun, 30 Jun 2024 17:23:38 GMT -
Rating 6
- Innovation 8
- Information 9
- Rumor 5
